Prima BioMed (NASDAQ: PBMD) announced they have recruited the next patients for its TACTI-mel clinical trial.
As quoted in the press release:
Patients with unresectable or metastatic melanoma that have had a suboptimal response to KEYTRUDA® were dosed with the higher 6 mg dose of IMP321 in combination with KEYTRUDA®.
Prima’s Chief Medical & Scientific Officer, Dr Frédéric Triebel, will be presenting the TACTI-mel clinical trial at the Immune Checkpoint Inhibitors conference at the Sheraton Hotel Boston, Massachusetts, held on March 15-16, 2017.
The presentation will be delivered at 1:30pm on Thursday 16 March, 2017 EDT.
A copy of these presentation slides will be made available on the Prima BioMed website.
Further information on the conference can be found at
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient’s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.